Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pneumococcal

- PMLiVE

Sutent gets FDA approval for early use in kidney cancer

Decision could help Pfizer combat competition from BMS' Opdivo and Yervoy

National Institute for Health and Care Excellence NICE logo

NICE backs two advanced breast cancer drugs after price cuts

An estimated 8,000 women will be eligible to receive the drugs due to discounts

- PMLiVE

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

Eli Lilly HQ

Lilly expands its immuno-oncology work with $1.8bn CureVac deal

Will work with the German firm to develop ‘next generation’ cancer vaccines

Sanofi reception

Sanofi earmarks €170m for new French vaccines facility

Will expand its Val de Reuil production unit

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

NICE backs Pfizer’s Xeljanz for RA

But UK’s cost-effectiveness watchdog removes two drugs from CDF

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

- PMLiVE

Pfizer spins out SpringWorks Therapeutics biotech

Former Pfizer VP Lara Sullivan takes the helm at the newly-formed company

- PMLiVE

Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

Germany and the UK will be the first to receive the skin cancer treatment

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo and Yervoy ace kidney cancer trial

Combined checkpoint inhibitors show improved survival versus standard therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links